Agilent CDx gets expanded approvals

Create PDF

The assay also gained approval as an aid in identifying patients with head and neck squamous cell carcinoma for treatment with Keytruda. Keytruda as a single agent is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 (combined positive score ≥1) as determined by an FDA-approved test.

Agilent Technologies, 800-227-9770